Navigation Links
ViewRay Demonstrates Potential Therapy Applications for MRI-Guided Radiation at ASTRO 2011

CLEVELAND, Sept. 29, 2011 /PRNewswire/ -- ViewRay™, Inc., a privately held medical device company, will present potential applications for MRI-guided radiotherapy at the annual meeting of the American Society for Radiation Oncology (ASTRO) October 2 – 4 in Miami Beach, Florida, with software demonstrations in booth #865. The company's new research radiation therapy system is being developed to feature a patented combination of radiotherapy delivery and simultaneous magnetic resonance imaging (MRI). The system is being designed to let radiation oncologists see what they're treating, while they're treating.

Visitors to ViewRay's ASTRO booth can view software demonstrations and learn about the key capabilities being designed into the system. In addition to quality pretreatment imaging and advanced treatment delivery, the ViewRay system is being developed to enable:

  • On-table dose prediction — fast dose prediction using volumetric image data captured just prior to treatment.
  • Soft-tissue targeting — continuous, MRI-guided tracking of soft tissues and automatic beam control for real-time adaptation to motion.
  • Adaptive optimization — fast, convenient reoptimization for effective online and offline plan adaptation.
  • Review and assessment — software tools that help physicians better understand and manage the progress of treatment.

ViewRay holds the exclusive worldwide license for its combination of MRI and radiation therapy technologies. Earlier this year, landmark patents were issued for ViewRay's core technology in both the United States and Europe. ViewRay's treatment planning and delivery software recently received 510(k) premarket notification clearance from the U.S. FDA, and its integrated imaging and radiotherapy delivery system is now pending 510(k) review. The ViewRay system is currently available only as a non–human use research system.

"With the 510(k) clearance of our software, the issuance of patents on our technology, and the addition of several new research partners, we've reached major milestones this year," said ViewRay President and CEO Gregory M. Ayers, MD, PhD. "We're looking forward to sharing our progress with the ASTRO community." ViewRay research partners now include the University of California, Los Angeles (UCLA) Health System – Jonsson Comprehensive Cancer Center, the University of Wisconsin Carbone Cancer Center, and the Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine, where the first ViewRay research system is currently being installed.

About ViewRay

ViewRay, Inc., of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The ViewRay system is being designed to provide continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians will be able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.

ViewRay is a trademark of ViewRay, Inc.

SOURCE ViewRay, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViewRay Wins NorTech Innovation Award
2. Siteman Cancer Center at Barnes-Jewish and Washington University to Receive First ViewRay Radiation Therapy System
3. ViewRay Secures Series C Financing
4. ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
5. University of Wisconsin Carbone Cancer Center to Acquire ViewRay Radiation Therapy System
6. Landmark Patents Issued for ViewRay Technology
7. UCLA Health System - Jonsson Comprehensive Cancer Center to Acquire ViewRay Radiation Therapy Research System
8. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
9. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Post Your Comments:
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
(Date:11/30/2015)... Nov. 30, 2015 NHS Supply Chain ... TrueBeam™ machines from Varian Medical Systems (NYSE: ... to replace older machines and institute modern radiotherapy ... public hospitals. The order, placed in September, also ... for Varian,s RapidArc® and Eclipse™ software systems.    ...
(Date:11/30/2015)... N.J. , Nov. 30, 2015  Novartis will ... at the 57 th American Society of Hematology ... lymphomas and myelomas as well as supportive care, including ... addition to personalized cell therapies. The ASH Annual Meeting ... Florida . Novartis Oncology . "We ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The ... this summer, ushering in a new era of publicly accessible automated technology. Now, ... will continue to offer guests an up-close look at the shuttle at MOSI’s ...
(Date:11/30/2015)... ... 2015 , ... On Saturday, October 24th, 2015, at the Mill Race Park ... a 5K walk known as “Making Strides Against Breast Cancer”. Patients and staff members ... located in Battle Creek, joined in for this campaign that sought to raise donations ...
(Date:11/30/2015)... ... 30, 2015 , ... During the week of Thanksgiving, the ... for its research, education, support, and advocacy efforts. The campaign is held every ... Mesothelioma Applied Research Foundation, which also goes by Meso Foundation, holds the ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to Los Angeles bariatric surgeon Michael ... not necessarily caused by real hunger, but instead by a hormone called ghrelin ... that, while many patients are aware that weight loss surgery can help patients lose ...
(Date:11/30/2015)... ... 30, 2015 , ... A record crowd gathered at the Pennsylvania Biotech Center ... Baruch S. Blumberg Institute. , The institute, which is the research arm of the ... leaders for the conference, which focused on ways companies can work to reduce the ...
Breaking Medicine News(10 mins):